开立医疗 reported revenue of ¥1.05B for the period ended 2026-06-30, +9.2% year on year. Net income was ¥0.01B, a 1.3% net margin on a 60.9% gross margin. The largest revenue line is 彩超 at 50% of the total. Free cash flow for the period was ¥0.01B.
| Item | Amount | Y/Y |
|---|---|---|
| Revenue | ¥1.05B | +9.2% |
| Gross profit | ¥0.64B | — |
| Operating income | ¥0.01B | — |
| Net income | ¥0.01B | -70.7% |
| Gross margin | 60.9% | Net margin 1.3% |
| Revenue Q/Q | +19.1% | — |
| Segment | Revenue | Share |
|---|---|---|
| 彩超 | ¥0.52B | 49.5% |
| 内窥镜及镜下治疗器具 | ¥0.43B | 40.9% |
| IVUS产品 | ¥0.07B | 6.2% |
| 其他主营业务 | ¥0.02B | 1.8% |
| 其他(补充) | ¥0.02B | 1.6% |
| Item | Amount | % of revenue |
|---|---|---|
| Cost of revenue | ¥0.41B | 39.1% |
| R&D | ¥0.23B | 21.7% |
| SG&A | ¥0.41B | 39.2% |
| Tax & other | ¥-0.01B | -0.5% |
| Item | Amount |
|---|---|
| Total assets | ¥4.09B |
| Total liabilities | ¥1.07B |
| Shareholders' equity | ¥3.02B |
| Equity / assets | 73.8% |
| Operating cash flow | ¥0.03B |
| Capital expenditure | ¥0.03B |
| Free cash flow | ¥0.01B |
| Cash conversion (OCF / net income) | -774% |
The Sankey chart shows how revenue splits into cost of revenue, R&D and SG&A, and what remains as profit — clean visuals for research decks and social posts.
彩讯股份 ・ 中达安 ・ 同和药业 ・ 扬帆新材 ・ 广和通 ・ 凯普生物 ・ 德艺文创 ・ 正丹股份 ・ 透景生命 ・ 万通智控 ・ 南京聚隆 ・ 正元智慧
Source: Eastmoney · This page shows public filing data only, not investment advice. · Browse all companies